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Background: A great challenge of cancer chemotherapy is to eliminate cancer cells and concurrently maintain the
quality of life (QOL) for cancer patients. Previously, we identified a novel anti-cancer bioactive peptide (ACBP), a
peptide induced in goat spleen or liver following immunization with human gastric cancer protein extract. ACBP
alone exhibited anti-tumor activity without measurable side effects. Thus, we hypothesize that ACBP and combined
chemotherapy could improve the efficacy of treatment and lead to a better QOL.
Results: In this study, ACBP was isolated and purified from immunized goat liver, and designated as ACBP-L. The
anti-tumor activity was investigated in a previously untested human gastric cancer MGC-803 cell line and tumor
model. ACBP-L inhibited cell proliferation in vitro in a dose and time dependent manner, titrated by MTT assay. The
effect of ACBP-L on cell morphology was observed through light and scanning electron microscopy. In vivo ACBP-L
alone significantly inhibited MGC-803 tumor growth in a xenograft nude mouse model without measurable side
effects. Treatment with the full dosage of Cisplatin alone (5 mg/kg every 5 days) strongly suppressed tumor growth.
However, the QOL in these mice had been significantly affected when measured by food intakes and body weight.
The combinatory regiment of ACBP-L with a fewer doses of Cisplatin (5 mg/kg every 10 days) resulted in a similar
anti-tumor activity with improved QOL. 18F-FDG PET/CT scan was used to examine the biological activity in tumors
of live animals and indicated the consistent treatment effects. The tumor tissues were harvested after treatment,
and ACBP-L and Cisplatin treatment suppressed Bcl-2, and induced Bax, Caspase 3, and Caspase 8 molecules as
detected by RT-PCR and immunohistochemistry. The combinatory regiment induced stronger Bax and Caspase 8
protein expression.
Conclusion: Our current finding in this gastric cancer xenograft animal model demonstrated that ACBP-L could
lower Cisplatin dose to achieve a similar anti-tumor efficacy as the higher dose of Cisplatin alone, through
enhanced modulation of apoptotic molecules. This newly developed combination regiment improved QOL in
tumor bearing hosts, which could lead to clinical investigation for the new strategy of combination therapy.
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Cancer is a genetic disease that is developed due to accu-
mulated multiple genetic defects along human life span.
The heterogenous natures of genetic and malignant phe-
notypes within each type of cancer create a great challenge
for cancer diagnosis and treatment [1]. At present the
time, a high percentage of cancer patients are incurable,
especially for solid tumors in late stage [2]. So, the quality
of life (QOL) is particularly important to patients with
advanced cancer, because most of them are symptomatic
when diagnosed [3,4]. In addition, repeated utilization
of chemotherapy agent nonspecifically kills proliferating
cells, which leads to significantly toxic side effects and de-
creased patient QOL [5]. Such nonspecific therapeutic
strategy induces chemo-resistance, which creates a situ-
ation of either further increasing chemotherapy dosage
with more severe toxicity or making patients intolerable
for treatment. Neither is a best therapeutic strategy for
cancer patients. Therefore, when treating cancer patients
at the intermediate or advanced stage, the evaluation of
patient outcomes should not just focus on the elimination
of tumor burden at the expense of cancer patient QOL.
Cisplatin is one of the first line chemotherapy agents for
treating advanced gastric cancer [6]. Previously, many clin-
ical trials have been conducted to find the best combinatory
regiment of Cisplatin with other chemotherapy agents, such
as Docetaxel and Fluorouracil [7]. However, cancer patient
QOL was ignored in many of the clinical trials because the
traditional way to evaluate the efficacy of cancer therapy
usually only relies on the index of cure rate and survival
rate. As recent bio-psyco-social models have been devel-
oped to evaluate total cancer patent condition as a whole
biological system, more attention has been drawn to the
QOL of cancer patients during treatment [8]. Currently,
QOL is one of several important indicators used to evaluate
the efficacy of treatment, which is not only based on clinical
objective indexes as evaluation standard, but also em-
phasizes subjective conditions of cancer patients [9].
For example, prospectively assessed QOL (even after
completion of protocol treatment) was proposed and
performed as one of the secondary end points of the
phase III trial of combined therapy of Docetaxel plus
Cisplatin and Fluorouracil for advanced gastric or gas-
troesophageal adenocarcinoma [10].
Anti-cancer treatments using biologically active mate-
rials, including bioactive peptides, have recently been
identified with potent anti-cancer activity and lack of side
effects [11-13]. Bioactive peptides exist naturally in living
beings such as animals, plants, and microorganisms. In
addition, these peptides can be produced through artificial
modification of biological materials, such as proteolysis of
tissues and serum from animals or plants; or synthetic
methods, such as chemical synthesis or biological engin-
eering. The naturally existing bioactive peptides play acrucial role in regulating biological activities, including
molecular recognition, signaling transduction, cell pro-
liferation, and differentiation. Previously, we identified
anti-cancer bioactive peptide (ACBP), which is such a
naturally existing peptide [14]. ACBP is a mixture of
several polypeptides with a molecular weight of about
8 kD, and isolated and purified from goat spleens or
livers after immunization with human gastric cancer
protein extracts. ACBP was analyzed using high per-
formance capillary electrophoresis (HPCE) and matrix-
assisted laser desorption-ionization time-of-flight mass
spectrometry (MALDI-TOF-MS) [15,16]. ACBP exhib-
ited multiple biological activities, including anti-tumor
activity in vitro and in vivo [14]. In addition, acute and
chronic toxicological tests in mice and rats showed no
measurable toxicities or side effects interfering with
normal physiological functions and enzyme metabol-
ism activities [17,18].
Based on the low toxicity of ACBP, we hypothesized that
ACBP could potentiate chemotherapy agent, enhance the
efficacy of treatment, and lower the chemotherapy dosage
to decrease drug induced side effects and toxicity. How-
ever, the combinatory effects of ACBP and chemotherapy
have never been investigated in animal tumor models. In
this study, we used a combined regiment of ACBP-L (from
liver) with a lower dosing Cisplatin, which could reach the
same anti-tumor efficacy as the higher dosing Cisplatin
alone in the xenograft nude mouse model bearing human
gastric cancer MGC-803. Decreased chemotherapy dosage
leads to improved QOL of tumor-bearing nude mice. The
molecular mechanisms of the combined therapy could be
regulated through the modulation of apoptotic molecules,
such as BAX, Bcl-2, Casapse 3, and Caspase 8. Our study
suggests that the combination of ACBP-L and chemother-
apy could be a new anti-cancer strategy, which is capable
of concurrently suppressing tumor growth and improving
host QOL.
Results
ACBP-L exhibited anti-tumor activity against MGC-803
cancer cells in a dose and time-dependent manner in vitro
To determine the effect of ACBP-L on cell proliferation,
MGC-803 cancer cells were treated with increasing con-
centrations of ACBP-L for 24 hrs and 48 hrs. Increased
ACBP-L (5.0-30.0 μg/mL) inhibited cell proliferation
in a dose dependent manner measured by MTT assay
(Figure 1a). The survival of MGC-803 cancer cells was
decreased by approximately 10.3%, 20.7%, 27.6%, 34.5%,
41.4%, and 58.6% after a 24 hr exposure to 5, 10, 15, 20,
25, or 30 μg/ml ACBP-L, respectively. The median con-
centration of inhibition (IC50) at 24 hrs was 28.50 μg/ml.
In addition, ACBP-L anti-proliferative effect on MGC-803
cells was persistent and increased with prolonged treating
time. The inhibitory rates at 48 hrs were: 27.3%, 31.8%,
Figure 1 ACBP-L exhibits anti-tumor activity against MGC-803 cancer cells in a dose and time-dependent manner in vitro. (a) ACBP-L
suppressed MGC-803 gastric cancer cell proliferation at a dose-dependent manner by MTT assay measured at the absorbance of 490 nm (A = 490 nm)
during 24 hr (left) and 48 hr (right) time points. The samples were measured in triplicates and the data were presented as mean ± standard deviation
(SD). The median concentration of inhibition (IC50) at 24 hr is 28.50 μg/ml, and at 48 hr is 17.96 μg/ml. (b) ACBP-L inhibited cell growth and induced
cell apoptosis in a dose dependent manner observed under light microscopy (400X). (c) Scanning electron microscopy showed cell membrane
damage after 48 hr ACBP-L treatment (shown in two different fields). Scale indicates 10 μM.
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17.96 μg/ml. We compared the inhibitory rates at the dif-
ferent time point and found that, a 48-hour treatment of
MGC-803 cancer cell with the 25 μg/ml concentration of
ACBP-L resulted in a 65.2% decrease in cell viability, com-
pared with a 41.4% decrease with 24-hour exposure to the
same concentration of ACBP-L (Figure 1a).
The cell morphology after different doses of ACBP-L
treatment was observed (Figure 1b). The cell morphology
resembled cell growth inhibition and an induction of cell
apoptosis. At the lower dose (10 μg/ml), fewer cells were
observed in the culture, and the remaining cells exhibited
the morphology of bleb, loss of cell membrane asymmetry,
and detachment. At the higher concentration (15 μg/ml),cell shrinkage and nuclear condensation were more appar-
ent. In addition, under the treatment of the highest concen-
trations of the two doses, cells completely lost membrane
and exhibited condensed nucleus, or only cell debris was
left (Figure 1b). Scanning electron microscope revealed a
consistent morphology that cell membrane was damaged
and lost asymmetry (Figure 1c).
ACBP-L potentiated the low dose Cisplatin treatment to
suppress gastric tumor growth in a xenograft tumor model
A xenograft nude mouse model was established with sub-
cutaneous inoculation of human gastric MGC-803 cancer
cells. The tumor growth rate was measured and calculated
at each time point, and the statistical significance of the
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group, tumor volume increased significantly shown by each
measurement, indicating an aggressive malignant pheno-
type with a fast tumor growth rate. The anti-tumor activity
of ACBP-L was tested by daily injection of 7 μg/mouse, and
compared with traditional regiment of Cisplatin alone at
5 mg/kg four times every five days. The regiments are the
essential dosages with anti-tumor activity identified from
pilot experiments (data not shown). To test if ACBP-L
could potentiate Cisplatin anti-tumor effects, we decreased
dose of Cisplatin to 5 mg/kg for every 10 days, with a total
of two injections, and combined with ACBP-L (7 μg/mouse
for daily injection). When compared the dynamic growth
rate of the control and the three treated groups, the tumor
growth rates were statistically different after treatment at
day 7. At the end of treatment, ACBP-L significantly inhib-
ited tumor growth by 61.3%, Cisplatin at the higher dose
exhibited strongest anti-tumor activity with an inhibitoryFigure 2 ACBP-L and low dose Cisplatin combined treatment suppres
ACBP-L suppresses tumor growth in vivo. The in vivo tumor growth experim
gastric cancer cells. After tumors were palpable and when the sizes of tum
with eight mice (n = 8) each into four groups: control with daily intraperito
Cisplatin alone (5 mg/kg every five days for 4 times, given the drug at day
daily ACBP-L. The tumor volumes were measured every three days (a). The
(b). The data were calculated and presented as mean ± standard deviation
difference was indicated as p < 0.05, when compared with the control gro
Tumor weight was measured after harvest, and the data were calculated a
(p < 0.05) was determined by Student t-test when compared with the conrate of 81.6% (Figure 2b, Student t test, p < 0.05). When
ACBP-L was combined with low dose of Cisplatin, the
treatment suppressed tumor growth at the similar rate as
the high dose of Cisplatin alone (Figure 2a). At the end of
the treatment, the combinatory treatment decreased
tumor growth by 78.3% (Figure 2b, Student t test, p <
0.05). After harvesting tumors at the end of the experi-
ment, the tumor weights of four experimental groups were
examined and compared: control, 0.90 ± 0.25 g; ACBP-L,
0.44 ± 0.05 g; Cisplatin, 0.21 ± 0.10 g; combination, 0.14 ±
0.04 g (Figure 2c, d). The inhibition rate was ACBP-L,
51.1%; Cisplatin, 76.7%; combined therapy 84.4%. The stat-
istical significance of tumor weights resembled those of
tumor volumes (Figure 2b, d). There are statistical differ-
ences observed when comparing each treated groups with
the control, however, high dose Cisplatin alone or combin-
atory treatment with low dose of Cisplatin exhibited the
strongest anti-tumor effect (Student t test, p < 0.05).ses gastric tumor growth in the xenograft tumor model.
ent was established by subcutaneous injection of 2×107 MGC-803
ors were about ~10 mm3, the tumor bearing mice were randomized
neal injection of saline, daily injection of ACBP-L (7 μg/mouse) alone,
6, 11, 16, 21), and Cisplatin (5 mg/kg, twice giving at day 6 and 16) plus
final tumor volumes were calculated before the end of experiments
(SD). Statistical significance was determined by Student t-test (statistical
up (*), or compared with ACBP-L treated alone group (#). (c and d)
nd presented as mean ± standard deviation (SD). Statistical significance
trol (*) and ACBP-L treated alone group (#).
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Ciaplatin improve quality of life in the xenograft
tumor model
When we examined the ACBP-L and Cisplatin anti-tumor
activity in vivo, we also observed the quality of life (QOL)
of tumor bearing animals. The QOL of ACBP-L and com-
binatory treated groups were significantly improved over
that of the high dose Cisplatin group, indicated by body
weight and food intake (Figure 3). The mice in the ACBP-
L or combinatory treated groups were more active, had
good appetite, and their appearance and body weight
were close to that of a normal mouse. The mice in the
group with high dosage of Cisplatin exhibited strong
gastrointestinal toxicity (diarrhea), systemic toxicity
(piloerection and lethargy), and a consistent decline in
body weight (Figure 3a). At the end of experiment,
there was no body weight loss in ACBP-L treatment
when compared to control. The body weight of the high
dose Cisplatin group was the lowest, and the body weight
of the combinatory treated group was slightly lower than
the control and ACBP-L treated groups (Student t test,
p < 0.05, Figure 3b).Figure 3 ACBP-L and low dose Cisplatin combined treatment improve
xenografted nude mice (n = 8) was measured every two days for thirty day
(b) Body weight was presented by mean ± (SD). Statistical significance wer
ACBP-L (#), and combined treatment (+), p < 0.05. (c) Food intake by tumo
group were presented. (d) Data of food intake were presented as mean ±
compared with the control (*), ACBP-L (#), and combined treatment (+), pQOL was also examined by daily food intake of the ex-
perimental animals (Figure 3c). There were three large
decreases of food intake in the Cisplatin alone group
after the mice were given the 1st, 2nd, 3rd doses of Cisplatin
at day 6, 11, and 16. In the combinatory treated group,
there were two decreased food intake corresponding to
the Cisplatin dosing at day 6 and 16. At the end of the ex-
periment, daily food intake by mice in the Cisplatin group
was significantly lower than that of the other three groups
(Figure 3d, Student t test p < 0.05).
High dose of Cisplatin alone decreased spleen weight in
the xenograft tumor model
The spleen index was measured as an indication of sys-
temic toxicity induced by Cisplatin (Figure 4a). There was
a significant decrease of spleen index in the high dose of
Cisplatin group when compared with the other three ex-
perimental groups, while the combination treatment group
did not show significant decrease of spleen index, indicating
less toxicity. However, no significant decrease of the liver
weight was observed in any of the experimental groups
(data not shown).s quality of life in the xenograft tumor model. (a) Body weight of
s, and means of the body weight of each group were presented.
e determined by Student t-test when compared with the control (*),
r bearing mice was measured every two days, and the means of each
SD. Statistical significance was determined by Student t-test when
< 0.05.
Figure 4 ACBP-L or Cisplatin alone, or combined treatment suppresses metabolic activities in tumor baring animals and in live tumor
cells in vivo. (a) Spleen weight of each mouse (n = 8) was measured after euthanasia. Mouse spleen index was calculated by mouse spleen
weight (mg) divided by the mouse body weight (g). Data are presented as mean ± SD from eight mice in each group. Statistical significance was
determined by Student t-test when compared with the control (*), ACBP-L (#), and combined treatment (+), p < 0.05. (b) 18F-FDG PET/CT fuse
imaging (cross section) from a representative nude mouse of each group is presented (CT image, left; PET image, right). Radioactivity uptake
represents the biological and metabolic activities of tumors (Target, T, black arrows) were compared with spine counts (Non-Target, NT) within
the identical section, as the T/NT ratio. The T/NT ratio is significantly decreased in treated groups when compared with the control.
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suppressed biological and metabolic activities in live
tumor cells by PET-CT image
Viability and metabolic activity of xenograft tumors from
four experimental groups were evaluated by 18F-FDG
PET/CT imaging (Figure 4b). PET with 18F-FDG is a non-
invasive approach for determination of the glycolyticstatus, and enhanced glycolysis is one of the most import-
ant characteristics of energy metabolism in cancer cells.
The higher the ratio of radioactivity uptake in tumor
versus normal area (Target/Non-target) indicates the
stronger glycolysis in tumor cells, suggesting more ener-
getic and aggressive tumor cell status. In this study, we
observed a significant difference in radioactivity uptake
Su et al. Cell & Bioscience 2014, 4:7 Page 7 of 13
http://www.cellandbioscience.com/content/4/1/7when comparing the Target/Non-target ratio of tumor/
spine (T/NT:1.39) in the control group with mice from
three treated groups, ACBP-L (T/NT:1.26), Cisplatin
(T/NT:1.18), and combined therapy (T/NT:1.19). Our data
suggested that all three treatment regiments decreased the
viability and metabolic activity of live tumor cells, where
comparable inhibitory effects were observed in higher dos-
ing Cisplatin treatment alone as the combined therapy of
ACBP-L with lower dosing of Cisplatin (Figure 4b).
ACBP-L and Cisplatin alone, or in combination, induced
molecules promoting cell apoptosis
We hypothesized that the anti-tumor activity of ACBP-L
could be mediated through promotion of tumor cell apop-
tosis. Pathological analysis after H&E staining of harvested
tumors showed more cells with apoptotic features in all
treated groups (Figure 5). Immunohistochemical staining of
proteins involved in apoptosis were performed and quanti-
fied, that significant differences in Bax, Bcl-2, Caspase 3,
and Caspase 8 expression were observed between the ex-
perimental groups with controls (Figure 5). Stronger Bax
staining was observed in ACBP-L alone and in the com-
bined treatment groups when compared with the control.
Decreased Bcl-2 expression was observed in all treated
groups. Induction of Caspase 3 and Casapse 8 were ob-
served in all treated groups, and a stronger response was
observed in the ACBP-L alone or the combinatory group
(Student t test, p < 0.05).
To further evaluate the molecular regulatory mechanism
induced by ACBP-L and Cisplatin alone, or by the com-
binatory treatment, we analyzed the important apoptotic
genes, such as Bax and Caspase 3 in tissue specimens by
semi-quantitative RT-PCR (Figure 6). Consistent with the
protein expression, Bax expression was significantly in-
creased in all groups after treatment, and the ACBP-L
alone and combinatory treated group exhibited a higher
induction (Figure 6b, left panel, Student t test, p < 0.05).
Caspase 3 expression was increased in all treated groups,
and ACBP-L induced the highest level of Caspase 3 ex-
pression (Figure 6b, right panel, Student t-test, p < 0.05).
All data strongly suggested that the molecular mechanism
of apoptosis was involved by treatments.
Discussion
In this study, the anticancer effect of ACBP-L in human
gastric cancer is demonstrated by suppression of cell line
MGC-803 proliferation in vitro by MTT assay and mor-
phological observations under light or electron micro-
scope (Figure 1). The IC50 of ACBP-L was in the range
of 18-28 μg/ml, with a dose and time dependent man-
ner. In vivo, ACBP-L exhibited potent anti-tumor effects
when used alone, and was able to potentiate Cisplatin
chemotherapeutic effect at the lower dose (Figures 2 and
4b). Such combinatory regiment significantly improvedthe QOL with lower systemic toxicity (Figures 3 and 4a).
The tumor specimens harvested from treated groups ex-
hibited increased apoptosis, detected by IHC and RT-PCR,
suggesting that the anticancer effect of ACBP-L was due
to induced apoptosis through Bax and Caspase mediated
mechanisms (Figures 5 and 6).
The novel finding of this study is that ACBP-L alone
exhibited potent anti-tumor activity, and additionally, to
potentiate Cisplatin chemotherapeutic effects with lower
systemic toxicity in vivo (Figures 2 and 3). Cisplatin is one
of the most broadly used chemotherapeutic agents for
treating cancers from the gastric region, the head and
neck, and other sites of the aerodigestic tract. However,
the high dosing and long-term administration of this
medication creates severe systemic toxicity, including
gastrointestinal problems, such as intense nausea and
vomiting, hair loss, myelosuppression, renal toxicity, and
hearing loss. To balance the efficacy of eliminating cancer
cells while maintaining the QOL of cancer patients is a
great challenge for the oncologist and drug development.
Our current study provides a new strategy of utilization of
natural existing bioactive peptides, such as ACBP-L used
in this study, to potentiate chemotherapeutic effects and
minimize toxic effects. In natural resources, broad spec-
trums of bioactive peptides exhibit regulatory activities
that are involved in different biological processes. These
natural peptides exist, but in the relatively low amounts or
at the low levels of activities. Using immunization protocol
with cancer tissue extracts is one way to enrich or activate
such naturally exiting peptides. During the process of the
isolation and purification of ACBP, we observed signifi-
cantly higher peaks of these peptides from the induced
liver or spleen, when compared with those isolated from
normal organs. The enrichment of the recovered peptides
is more than three folds after the purification (Su X, un-
published observations). In addition, we compared the
anti-tumor activity between the peptides isolated from
normal or induced spleens, using the same amount of ma-
terials. We observed both normal or induced peptides ex-
hibited anti-tumor proliferation activity in vitro using
MTT assay. However, a stronger inhibition of tumor cell
proliferation, near two-fold increase, was observed in the
peptides from induced spleens when compared with the
peptides isolated from normal spleens (Su X, unpublished
observations). We also compared the peptide biochemical
profiles of ACBP isolated from goat spleens [14] or livers,
which exhibited similar elution time and characteristics of
elution peaks through MPLC (data not shown). Further-
more, ACBP not only exhibited anti-tumor activity of gas-
tric cancer lines MGC803 as shown in this manuscript
and SGC-7901 (unpublished data), but also exhibited a
broad activity of anti-tumor effects in different cancer
types in vitro and in vivo, regardless immunized cancer
types, suggesting it seems not related to specific immune
Figure 5 ACBP-L or Cisplatin alone, or combined treatment induces molecules promoting cell apoptosis in vivo. (a) Paraffin embedded
tumor specimens (n = 8/each group) were stained with HE and immunohistochemistry of Bax, Bcl-2, Caspase 3, and Caspase 8, (low magnification
40X, high magnification 400X). (b) The quantitation of IHC scores were analyzed, the statistical significance was determined by Student t-test
(p < 0.050), and data are presented as compared with control (*), ACBP-L (#), and Cisplatin treated group (+).
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to show the broad anti-tumor activity of ACBP in human
myelogenous leukemia line K562 [19], human nasopha-
ryngeal carcinoma line CNE [20], human cholangiocarci-
noma cell line QBC939 [21], murine hepatocarcinoma line
H22 [22], and human breast cancer line nm231 [23], hu-
man colon adenocarcinoma cell line HT29 [24]. However,
ACBP showed minimal inhibitory effects on normal cells
that we tested, such as human skin fibroblast HS-68 cellsand rabbit bone marrow mesenchymal stem cells (Su X,
unpublished data). The exact molecular mechanisms of the
broad anti-tumor activities and preference against tumor
but not normal cells are under investigation. Consistent
with the observations in vitro, ACBP exhibited minimal
side effects in vivo (Figure 2). This supports to test ACBP
anti-tumor activity in future clinical trials for cancer pa-
tients. In addition, one of the advantages for isolating
ACBP-L from liver is the higher yield, which is more than
Figure 6 Combined ACBP-L and Cisplatin treatment strongly induces anti-tumor activity in tumors Specimens. (a) Semi-quantitative
RT-PCR was performed to detect gene expression of Bax and Caspase 3 in tumor specimens (n = 5). RT-PCR products were run on 2% agarose
gel, and gel images were shown with the indicated molecular weight. (b) The ratio of Bax and Caspase 3 gene expression were calculated and
presented as mean ± standard deviation (SD), and the significant difference was examined by Student t-test (p < 0.050), and presented as
compared with control (*), ACBP-L (#), and Cisplatin (+).
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harvested from spleen (data not shown). The high yield
enables us to improve production efficiency and feasibility
study of future clinical trials.
In this manuscript, we examined whether ACBP-L could
be used as a new adjuvant agent to enhance chemothera-
peutic efficacy and reduce toxicity in the treatment of can-
cer patients. Consistent with the potent anti-cancer effects
as previously seen using ACBP from the spleen, in this
study, the effects of ACBP-L on the QOL has been demon-
strated intuitively by the maintenance of normal body
weight when using ACBP-L alone (Figure 3a, b), in contrast
to a continuing decreased body weight observed due to the
toxic effects of high dosing of Cisplatin alone. Further, the
combinatory treated group with lower dosing of Cisplatin
exhibited similar anti-tumor effects with a continuing re-
covery of the body weight that eventually reached normal
level (Figure 3a, b). In addition, the QOL was also indicated
by average daily food intake, which showed that the amount
of food intake in mice treated with high dosing Cisplatin
significantly dropped after each treatment. Although, in the
combinatory treated group, significant decreased food in-
takes occurred similarly to the Cisplatin alone group, but
the mice recovered quickly and gradually returned to a nor-
mal level of food intake. We also observed the suppression
of the spleen index in the high dosing of Cisplatin group,
but not in the combinatory treated group (Figure 4a). The
data suggest that high dosing of Cisplatin could suppress
the host immune and defense systems, but the combinatory
treated group did not suffer from side effects. Our data
strongly support the notion that the combination of che-
motherapeutic agents with natural anti-cancer bioactivepeptides could be a new strategy for more efficiently treat-
ing cancer patients while maintain QOL.
We observed that the viability and metabolism in live
tumors exhibited significantly decreased in all three
treated groups measured by 18F-FDG PET/CT in the live
animals (Figure 4b). Integrated PET/CT with 18F-FDG is a
hybrid of radiation and imaging modalities, which has
been recently established in the staging, restaging and
therapy response assessment of oncology patients [25].
The machine is capable to determine the glycolytic status
in tissues, through an image that shows the tissue distribu-
tion of the positron emitter from 18F-FDG, a structural
analog of glucose. Enhanced glycolysis is one of the most
important characteristics of live cancer cells. 18F-FDG
PET/CT has been proven to be successful as a diagnostic
instrument for many solid tumors, including gastric can-
cer, especially for follow-up after cancer treatment, be-
cause it indicates the energy metabolism and viability of
the tumor cells [25,26]. In this study, 18F-FDG PET/CT
method clearly showed consistent results with other bio-
logical and molecular measurements, with an advantage of
monitoring the anti-tumor effect of different treatments
without interrupting the ongoing animal experiment.
Further, ACBP-L induced cell death of tumors also well
documented at the cellular level, with morphology of bleb,
loss of cell membrane asymmetry and detachment, cell
shrinkage, and nuclear condensation (Figure 1b, c). The al-
tered cell morphology is consistent with the molecular
mechanism of triggering apoptotic pathways involving BCL
and Caspase family members. At the protein level, a signifi-
cant increase of Bax in ACBP-L alone and in the combin-
atory groups, and a significantly decreased Bcl-2 in the
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suggesting that the mechanisms involved could be slightly
different. Consistent with the protein expression, Bax
expression at the mRNA level was also strongly induced in
the ACBP-L alone and in the combinatory treated groups
(Figure 6). The Bcl family, whose members may be antia-
poptotic (such as Bcl-2) or proapoptotic (such as Bax),
regulates cell death by controlling the mitochondrial mem-
brane permeability during apoptosis [27]. Bax is a 21-kD
program partner associated with Bcl-2, and exhibits an
extensive amino acid homology with Bcl-2 and forms
homo- or heterodimers with Bcl-2 in cells. When BAX pre-
dominates, programmed cell death is accelerated, and the
death repressor activity of Bcl-2 is countered, such that the
ratio of Bcl-2 to BAX determines survival or death follow-
ing an apoptotic stimulus [28].
While anti-apoptotic effect of Bcl-2 is through the inhib-
ition of the release of Cytochromum C from mitochondria
for Caspase activation [29-31], all three treated groups also
exhibited an induction of Caspase protein and mRNA ex-
pression (Figures 5 and 6). A relatively stronger induction
of Caspase 3 was observed in the ACBP-L treated group,
while a stronger induction of Caspase 8 was observed in
the combinatory treated group (Figure 5). In apoptosis cell,
Caspase initiates the opening of the Permeability Transition
(PT) aperture of the mitochondria and regulates apoptosis
via regulating transmembrane electrochemical gradient
[32]. The mechanisms of ACBP-L induced apoptosis
are consistent with the apoptotic morphology of al-
tered and destroyed cell surface membrane and struc-
ture observed through light and scanning electron
microscopes (Figure 1b, c) [33-35].
Conclusions
We showed that ACBP-L potently inhibited gastric cancer
cell proliferation and induced apoptosis in vitro. ACBP-L
alone exhibited potent anti-cancer effects and potentiated
Cisplatin chemotherapeutic effects in vivo. ACBP-L alone,
or combined with lower dosing of Cisplatin, significantly
improved host QOL without compromising therapeutic ef-
fects. ACBP-L and combinatory therapy induced cell apop-
tosis through modulation of BCL and Caspase pathways.
Our study suggests that ACBP-L alone, or in combination
with chemotherapy agents, could enhance anti-cancer ef-
fects and improve patient QOL, which could be a new
therapeutic approach for further development against gas-
tric or other neoplasms.
Material and methods
Production and purification of ACBP-L from immunized
goat liver
The research involved with human subjects were per-
formed following "Ethical Principles for Medical Research
Involving Human Subjects". Anonymously primary humangastric tissue samples were obtained from The Affiliated
Hospital, Inner Mongolia Medical University, with the
approval of the Ethics Committee of Inner Mongolia
Medical University, (2012-SWLL-001). All animal experi-
ments were carried out under protocols approved by the
Animal Care and Use Committee of the Inner Mongolia
Medical University, and were in compliance with the inter-
national guidelines (Guide for the Care and Use of Labora-
tory Animal Resource, National Research Council, USA).
ACBP-L was produced and extracted using the following
steps. Goats were immunized five times with an interval
of one week through a series of injections with human
gastric cancer extracts. The livers were harvested from im-
munized animals. The tissues were subjected to several
rounds of ultrasonication (Ultrasonic Disrupter, Model
F525 from FLUKO Company, China). After centrifugation
at 14,000 rpm for 10 min, the supernatants were collected
and ACBP-L was isolated through mesolow preparative li-
quid chromatography (MPLC, Model YFLC-AI-580 from
YAMAZEN corporations, Japan). MPLC is a commonly
used protein and peptide purification chromatography,
which can separate relatively large amount of materials.
The molecular weight of eluted ACBP-L is ~8000 Dalton
based on measurement with SDS-PAGE gels [14]. ACBP-L
was included in an invention patent of Dr. Su Xiulan’s
ACBP-L laboratory and is protected by the Chinese na-
tional patent bureau (patent number: ZL96122236.0, and
international patent: A61K35/28).
Cell culture
Gastric adenocarcinoma cell line MGC-803 was kindly
provided by Professor Ke Yang (Beijing University,
Health Center, Beijing, China). Cells were maintained in
RPMI1640 culture medium (Invitrogen, USA), which
was supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS, TBD Science, China), 100U/ml peni-
cillin, and100 U/ml streptomycin, and cultured in a
humidified atmosphere of 5% CO2 at 37°C.
MTT assay
Cell proliferation was measured by MTT assay [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
TBD Science Co., China]. MTT was dissolved in sterile
PBS at room temperature, sterilized by passing through
a 0.22 μm filter, and stored in the dark at 4˚C. MGC-
803 human gastric cells (5×103/well) were placed in
200 μl of culture medium and incubated overnight.
After 24 h, cultures were treated with various doses of
ACBP-L in triplicates. MTT reagent (20 μl) was added
at different time points and then incubated at 37˚C for
4 h. Following vibrating on a shaker for 10 min, the
plates were measured for absorbance at 490 nm wave-
length using a microtiter plate reader. Drug concentra-
tions that inhibited proliferation by 50% (IC50 values)
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sion modeling of the logarithmic form of the equation.
Scanning electron microscope
MGC-803 cells were cultured in RPMI-1640 medium
containing 20 μg/ml of ACBP-L for 48 hrs. All cells were
fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.2) at 4°C for 1 hr. The samples were rinsed in
0.1 M cacodylate buffer several times, and then dehy-
drated in graded concentrations of alcohol. The ultrathin
sections were dried with Vacuum plating apparatus and
treated by spray-gold with ion sputtering equipment
(JEOL Company, USA). Then the specimens were exam-
ined with a S-3400 N scanning electron microscope
(JEOL Company, USA) operated at 15 KV.
Xenograft tumor model and administration of ACBP-L
and Cisplatin
All animal experiments were carried out under the proto-
col approved by the Animal Care and Use Committee of
the Inner Mongolia Medical University, as previously
described. Five-week-old athymic nude female mice
(BALB/c nu/nu, Institute of Laboratory Animal Sciences,
Chinese Academy of Medical Sciences, Beijing, China)
were housed in a sterile animal facility and inoculated with
MGC-803 cells (2 × 107) in 0.2 ml of PBS subcutaneously.
All mice developed single palpable tumors, with the aver-
age volume of the tumors equaling ~10 mm3 at day 3, fol-
lowing inoculation. The mice were then randomized into
four groups, including control, ACBP-L alone, Cisplatin
alone, and ACBP-L plus Cisplatin. Each group contained
8 mice (n = 8). The drugs were administered via intraperi-
toneal injection as follows: control: 0.2 ml of 0.9% NaCl
daily for 30 days; ACBP-L alone: 7 μg/mouse ACBP-L
in 0.2 ml daily for 30 days (ACBP-L batch#2008-10);
Cisplatin alone: 5 mg/kg every 4 days for total 4 doses, at
day 6, 11, 16, 21, according to the manufacturer’s protocol
(batch# 806027CF, Qilu Medicine Ltd, Jinan, China). The
combinatory treatment group of ACBP-L and Cisplatin:
7 μg/mouse ACBP-L in 0.2 ml daily for 30 days plus
5 mg/kg Cisplatin twice every 10 days at day 6 and 16.
The mouse body weight, the amount of water and food in-
take, as well as vital signs and living status, were checked
daily. Tumor volume was measured and calculated as
follows: the longer diameter, designated as “a”, and the
shorter one as “b” of the tumors were measured by Ver-
nier calipers, and the tumor volume (TV) was calculated
using the equation: TV = ab2/2. The growth curve of tu-
mors was plotted using the mean and standard deviation.
Measurement of body weight, food intake and collection
of tumor specimens
Body weight was measured once every other day, and
food intake was measured by weighing the food left inthe cage. To calculate the average daily food intake per
mouse in a cage, the amount of food present was sub-
tracted from that of the previous day, and then divided by
the number of mice in the cage. After euthanasia, tumors,
livers, and spleens were collected, weighed, and dissected.
The spleen index was calculated by the spleen weight mea-
sured in mg versus the mouse body weight measured in
grams. Portions of tissues were frozen at -80°C, and por-




18F-deoxyglucose (18F-FDG) Positron radioactive tracer was
synthesized by medical cyclotron (MINITrace, General
Electric Co., Milwaukee, USA) and FX-FN chemosynthesis
system (TraceLab, General Electric Co.). Mice were anes-
thetized by Ether 60 min after tail intravenous injection of
0.2 millicurie (mci) 18F-FDG and scanned systemically by
2D positron-emission tomography-computed tomography
(PET-CT). Figures from PET-CT were analyzed in Xeleris
by two experienced radiologists. The abnormal thick, thin,
or defect of radioactivity uptake in inoculation site was ex-
cluded. Radioactivity uptake from tumor (Target) was di-
vided by uptake from spine (Non-Target) and presented as
Target/Non-Target ratio (T/NT).
Immunohistochemistry (IHC)
Paraffin embedded tissues were sectioned at a thickness
of 4um, and stained with hematoxylin and eosin, and
immunohistochemistry (IHC). IHC protocol was modi-
fied from S-P Method (Maixin Biological Technology
Development Co., Fuzhou, China). Briefly, after depar-
affin, antigen retrieval was carried out in a microwave
oven for 10 min. The antibodies used were mouse anti-
human Bax antibody (90107254D1); mouse anti-human
Bcl-2 antibody (90104014 F1), from Maixin Biological
Technology Development Co.; rabbit anti-Caspase3
(KGA717, Keygene Biological Technology Develop-
ment Co., Nanjing, China); and rabbit anti-Caspase 8,
(Santa Cruz Biotechnology Co., Santa Cruz, CA, USA).
S-P hypersensitive kits (mouse and rabbit, 812059710)
and DAB reagents (806180031) were from Maixin
Biological Technology Co. Sections were stained with 3, 3-
diaminobenzidine (DAB), counterstained with haematoxylin,
and dehydrated in xylene, and mounted. The immunohisto-
chemical staining was observed under light microscope
(Olympus, Tokyo, Japan), and quantified by Olympus CX41
image analysis system.
Total RNA extraction and RT-PCR
Total RNA was extracted from tumor specimens using
TRIZOL reagent (Invitrogen, USA) according to the
manufacturer’s protocol. The quality and concentrations
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eter (Beckman, USA). Reverse transcription was per-
formed using an RNA PCR Kit (AMV) Version 3.0
(TaKaRa Co., Japan), and the reaction mixture contained:
1 μg RNA sample, 1 μl 10 × buffer, 1 μl dNTP (2 mmol/l),
0.5 μl oligo-dT primer (0.25 μM), AMV RTase 10 U,
RNase inhibitor 5 U and DEPC ddH2O up to 10 μl. The
mixture was kept at room temperature for 10 min, then
was incubated at 42°C for 30 min and at 99°C for 5 min.
PCR was performed in 25 μl reaction mixture which con-
sisted of 2 μl reverse transcription products, 5 μl 5X buf-
fer, 0.5 μl each gene specific primers (20 pmol/L), 0.5 μl
10 mM dNTP, 0.75 U Taq DNA polymerase (TaKaRa Co,
Japan), with ddH2O added up to 25 μl. PCR cycle parame-
ters were conducted with a pre-amplification denaturation
at 94°C for 2 min, followed by 35 cycles of denaturation at
94°C for 30 sec, annealing at 58°C to 65°C for 30 sec, and
extension at 72°C for 1 min, with a final extension at 72°C
for 5 min. GAPDH was used as an internal control. Ampli-
fied PCR products were visualized in a 2% agarose gel elec-
trophoresis containing ethidium bromide. Ratios amplified
gene/GAPDH was calculated by software Imagetool 2.0
(University of Texas Health Science Center, San Antonio,
Texas, USA). PCR results were confirmed by three repeat
amplifications. The sequences of PCR primers were de-
signed using GenBank database and the BLAST program.
All primers were synthesized commercially by the TaKaRa
Company (Dalian, China), and the experimental condition is
presented in Additional file 1: Table S1.
Data processing and statistic analysis
The calculation of tumor inhibition rate was based on the
equation described as follows: Tumor inhibition rate =
(tumor weight of control group of saline – tumor weight
of medicine group)/tumor weight of control group of sa-
line × 100%.
Data are presented as the mean ± standard deviation
(SD). Statistical analysis was performed using t test for
two groups, p <0.05 was considered statistically significant.
All statistical analyses were performed using an SPSS pro-
gram (version 13.0).Additional file
Additional file 1: Table S1. The experimental condition of RT-PCR.
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